Effectiveness and safety of risankizumab in HIV patients with psoriasis: A case series
Diego Orsini, Fabio Stefano Maramao, Luigi Gargiulo, Luciano Ibba, Francesco Piscazzi, Alessia Pacifico, Alessandra Latini, Laura Gianserra, Antonio Cristaudo, Antonio Costanzo, Alessandra Narcisi
Abstract
Biological therapies represent the gold-standard treatment of severe forms of plaque psoriasis. However, people living with HIV are often under-treated for psoriasis because very limited data are available on the use of biologics in this population. We report four cases of patients affected by HIV and moderate-to-severe plaque psoriasis, all treated with risankizumab, a monoclonal antibody that selectively targets interleukin-23. After 16 weeks, all patients experienced complete or almost complete skin clearance without any adverse events. Data on the effectiveness and safety of biological therapies in people living with HIV are limited to case reports or small case series, especially for the most recently approved inhibitors of interleukin-23. Our experienced, although limited, supports the role of risankizumab as a safe and effective therapy for psoriasis amongst patients living with HIV.